01

Litifilimab Sustains Skin Clearance Through 52 Weeks in Cutaneous Lupus

Litifilimab, an investigational type I interferon-targeting biologic, maintained durable skin clearance through 52 weeks in patients with cutaneous lupus erythematosus.